Gemcitabine for relapsed or resistant lymphoma
Authors:
Open Access
- 1 May 2000
- journal article
- clinical trial
- Published by Elsevier in Annals of Oncology
- Vol. 11 (5) , 595-598
Abstract
No abstract availableKeywords
This publication has 12 references indexed in Scilit:
- The role of single-agent gemcitabine in the treatment of non-small-cell lung cancerAnnals of Oncology, 1999
- Experimental drugs and drug combinations in pancreatic cancerAnnals of Oncology, 1999
- Phase II trial of gemcitabine as prolonged infusion in metastatic breast cancerAnti-Cancer Drugs, 1999
- Gemcitabine Is Active in Relapsed Hodgkin's DiseaseJournal of Clinical Oncology, 1999
- Therapy with gemcitabine in pretreated peripheral T-cell lymphoma patientsAnnals of Oncology, 1998
- Clinical results of a pharmacodynamically-based strategy for higher dosing of gemcitabine in patients with solid tumorsAnnals of Oncology, 1998
- Prolonged infusion gemcitabine: a clinical phase I study at low- (300 mg/m2) and high-dose (875 mg/m2) levelsInvestigational New Drugs, 1997
- Maximum-tolerated dose defined for single-agent gemcitabine: a phase I dose-escalation study in chemotherapy-naive patients with advanced non-small-cell lung cancer.Journal of Clinical Oncology, 1997
- A phase I study of a 24 hour infusion of gemcitabine in previously untreated patients with inoperable non-small-cell lung cancerBritish Journal of Cancer, 1996
- Comparison of antineoplastic activity of 2',2'-difluorodeoxycytidine and cytosine arabinoside against human myeloid and lymphoid leukemic cellsAnti-Cancer Drugs, 1991